Table 3.
Visual Acuity Outcomes by Randomized Treatment Group
| Visual Acuity | All | Aflibercept | Bevacizumab | Ranibizumab |
|---|---|---|---|---|
| N | 312 | 112 | 96 | 104 |
| VA, letters, mean (SD) | ||||
| Baseline | 65.7 (11.0) | 66.3 (11.5) | 64.6 (10.8) | 66.1 (10.8) |
| Year 2* | 77.8 (12.2) | 78.7 (10.7) | 74.4 (15.3) | 80.0 (9.5) |
| Year 5 | 72.8 (16.4) | 74.1 (15.3) | 70.7 (18.7) | 73.4 (15.0) |
| 5-Year VA Snellen group, N (%) | ||||
| 20/25 or better (≥79 letters) | 146 (47%) | 58 (52%) | 37 (39%) | 51 (49%) |
| 20/32 - 20/40 (69-78 letters) | 83 (27%) | 28 (25%) | 31 (32%) | 24 (23%) |
| 20/50 - 20/160 (39-68 letters) | 67 (21%) | 20 (18%) | 22 (23%) | 25 (24%) |
| 20/200 or worse (≤38 letters) | 16 (5%) | 6 (5%) | 6 (6%) | 4 (4%) |
| VA change from baseline to 5 years, N (%) | ||||
| ≥15 letter improvement | 94 (30%) | 34 (30%) | 27 (28%) | 33 (32%) |
| 10-14 letter improvement | 54 (17%) | 19 (17%) | 19 (20%) | 16 (15%) |
| 5-9 letter improvement | 50 (16%) | 17 (15%) | 14 (15%) | 19 (18%) |
| ±4 letter difference | 66 (21%) | 25 (22%) | 20 (21%) | 21 (20%) |
| 5-9 letter worsening | 17 (5%) | 5 (4%) | 6 (6%) | 6 (6%) |
| 10-14 letter worsening | 8 (3%) | 2 (2%) | 3 (3%) | 3 (3%) |
| ≥15 letter worsening | 23 (7%) | 10 (9%) | 7 (7%) | 6 (6%) |
*
VA data at the last available Protocol T visit were used for 5 participants that were missing VA at the 2-year visit. Abbreviations: SD = standard deviation; VA = visual acuity.